8-K: Bioventus to Divest Advanced Rehabilitation Business to Accelmed Partners for $45 Million

Bioventus has agreed to sell its Advanced Rehabilitation business to Accelmed Partners for a total consideration of $45 million, including potential earn-out payments.

Summary

• Bioventus Inc. has entered into an agreement to sell its Advanced Rehabilitation business, part of its subsidiary Bioness, to Accelmed Partners.
• The total consideration for the transaction is $45 million, which includes $25 million in cash at closing, subject to working capital adjustments, and up to $20 million in potential earn-out payments.
• Bioventus expects to net approximately $20 million after fees and expenses at closing, which will be used to repay existing debt.
• The divestiture is expected to reduce Bioventus' annual revenue by approximately $50 million and annual Adjusted EBITDA by approximately $6 million.
• The transaction is anticipated to close in the fourth quarter of 2024, pending customary closing conditions.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The divestiture allows Bioventus to focus on its core business and improve its financial position, while the buyer is enthusiastic about the acquisition. However, there is a reduction in revenue and EBITDA.

Positives

• The divestiture allows Bioventus to focus on its core business and enhance its liquidity.
• The sale will provide Bioventus with approximately $20 million in net proceeds to repay existing debt.
• Accelmed Partners intends to invest in developing and extending the product line of the Advanced Rehabilitation business.

Negatives

• The divestiture will reduce Bioventus' annual revenue by approximately $50 million.
• The divestiture will reduce Bioventus' annual Adjusted EBITDA by approximately $6 million.

Risks

• The transaction is subject to customary closing conditions, which may delay or prevent the closing.
• There is a risk that the earn-out payments may not be fully realized.
• The reduction in revenue and EBITDA may impact Bioventus' financial performance.

Future Outlook

Bioventus will focus on its core business and enhance liquidity, while Accelmed Partners will invest in the growth of the Advanced Rehabilitation business.

Management Comments

• Rob Claypoole, Bioventus' President and CEO, stated that the divestiture allows Bioventus to focus on its core business and enhance liquidity.
• Dr. Uri Geiger, Managing Partner of Accelmed, expressed excitement about adding the Advanced Rehabilitation business to their portfolio and investing in its growth.

Industry Context

This divestiture reflects a trend of companies focusing on core competencies and divesting non-core assets. It also highlights the continued interest of private equity firms in the HealthTech sector.

Comparison to Industry Standards

• The divestiture of a non-core business unit for a combination of cash and earn-out is a common practice in the healthcare industry.
• The valuation of the Advanced Rehabilitation business at approximately 0.9x annual revenue is within the range of similar transactions in the medical device sector.
• The use of proceeds to repay debt is a typical strategy for companies seeking to improve their financial position.

Stakeholder Impact

• Shareholders: The divestiture is expected to improve Bioventus' financial position and focus on core business.
• Employees: The employees of the Advanced Rehabilitation business will transition to Accelmed Partners.
• Customers: The customers of the Advanced Rehabilitation business will continue to receive products and services from Accelmed Partners.
• Creditors: The net proceeds from the divestiture will be used to repay existing debt.

Next Steps

• The transaction is subject to customary closing conditions and is expected to close in the fourth quarter of 2024.
• Bioventus will use the net proceeds to repay existing debt.
• Accelmed Partners will invest in developing and extending the product line of the Advanced Rehabilitation business.

Key Dates

Keywords

Bioventus, Accelmed Partners, Advanced Rehabilitation, Divestiture, Bioness, HealthTech, Earn-out, Debt Repayment, Financial Transaction, Private Equity